Shares in German biotech MorphoSys firm could double as the royalties start to roll in, says Mike Tubbs.
Articles written by Dr Mike Tubbs
You might not think of the UK as a market full of promising tech stocks. But our small- and medium-sized companies are punching above their weight, says Dr Mike Tubbs.
Biotech company Biogen’s promising treatment for the most common cause of dementia has just cleared a key hurdle.
Firms with strong brands, superior products or that exploit network effects are hard for competitors to keep up with. That means big profits for their investors. Mike Tubbs picks the best protected companies.
RWS is a “picks-and-shovels” play for the technology sector, and boasts an excellent record, says Mike Tubbs.
Science and engineering departments are innovation incubators, and regularly launch companies involved in a wide range of exciting new fields. Dr Mike Tubbs explains how to invest in spin-outs.
Safety specialist Halma capped its remarkable run by entering the FTSE 100 – but more will come.
ASML’s cutting-edge technology will capitalise on the growing demand for computer chips, says Mike Tubbs.
Investing in a booming industry can be a risky business – only a lucky few will strike gold and produce the hot products of the future. There’s a much safer way to bet on fast-growing sectors, says Dr Mike Tubbs.
Reading your genome is becoming easier and cheaper. That makes it possible to figure out which medicines will work for you. Dr Mike Tubbs picks the companies best-placed to profit.